CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$203.18M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 2.55: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.80TKRW2.02B · vs all stocks (USD)
Revenue (TTM)
659.27BKRW475.54M · vs all stocks (USD)
Profit Margin
-12.85%vs Biotechnology peers
Beta
0.8800xvs all stocks
52-Week Change
-28.34%vs all stocks
Market Capitalization
2.80TKRW2.02B · vs all stocks (USD)
Enterprise Value
2.71TKRW1.96B · vs all stocks (USD)
Forward P/E
-36.88xvs Biotechnology peers
Price to Sales (TTM)
4.18xvs Biotechnology peers
Price to Book (MRQ)
1.39xvs Biotechnology peers
Enterprise to Revenue
4.12xvs Biotechnology peers
Enterprise to EBITDA
-82.16xvs Biotechnology peers
Gross Margin
26.67%vs Biotechnology peers
Profit Margin
-12.85%vs Biotechnology peers
Operating Margin
-10.11%vs Biotechnology peers
Return on Assets (TTM)
-2.81%vs Biotechnology peers
Return on Equity (TTM)
-4.25%vs Biotechnology peers
Revenue (TTM)
659.27BKRW475.54M · vs all stocks (USD)
Revenue per Share (TTM)
8.41KKRWUpdated Sep 21, 2026Quarterly Revenue Growth
-3.80%vs Biotechnology peers
Gross Profit (TTM)
93.53BKRW67.46M · vs all stocks (USD)
EBITDA (TTM)
-33.04BKRW-23.83M · vs all stocks (USD)
Net Income (TTM)
-84.70BKRW-61.09M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-3.80%vs Biotechnology peers
Operating Cash Flow (TTM)
4.47BKRW3.22M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-281.68BKRW-203.18M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
248.65BKRWFY2025 · Dec 31, 2025Revenue
651.37BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
575.44BKRWFY2025 · Dec 31, 2025Gross Profit
75.92BKRWFY2025 · Dec 31, 2025Operating Income
-123.50BKRW-89.08M · vs all stocks (USD)
Pre-tax Income
-85.86BKRWFY2025 · Dec 31, 2025Income Tax Expense
-29.69BKRWFY2025 · Dec 31, 2025Net Income
-56.17BKRWFY2025 · Dec 31, 2025EBIT
-76.46BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-26.80BKRWFY2025 · Dec 31, 2025Research & Development
69.86BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
48.22BKRWFY2025 · Dec 31, 2025Other Operating Expenses
2.13BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
15.67BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
9.40BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-56.17BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.25BKRWFY2025 · Dec 31, 2025Operating Cash Flow
47.79BKRWFY2025 · Dec 31, 2025Free Cash Flow
-83.94BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
105.55BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-56.17BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-6.31BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-19.88BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
130.16BKRWFY2025 · Dec 31, 2025Capital Expenditures
-131.74BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-77.26BKRWFY2025 · Dec 31, 2025Net Acquisitions
-3.61BKRWFY2025 · Dec 31, 2025Purchase of Investments
-349.68BKRWFY2025 · Dec 31, 2025Sale of Investments
198.91BKRWFY2025 · Dec 31, 2025Other Investing Activity
1.62BKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-284.50BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
50.05BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
50.84BKRWFY2025 · Dec 31, 2025Shares Outstanding
78.46MSharesUpdated Sep 21, 2026Float Shares
25.61MSharesUpdated Sep 21, 2026% Held by Insiders
68.69%vs all stocks
% Held by Institutions
3.43%vs all stocks
Total Cash (MRQ)
832.60BKRW600.57M · vs all stocks (USD)
Total Cash per Share (MRQ)
10.67KKRWUpdated Sep 21, 2026Total Debt (MRQ)
543.37BKRW391.94M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2707xvs Biotechnology peers
Current Ratio (MRQ)
3.60xvs Biotechnology peers
Book Value per Share (MRQ)
25.69KKRWUpdated Sep 21, 2026Total Assets
2.96TKRW2.13B · vs all stocks (USD)
Total Current Assets
1.25TKRWFY2025 · Dec 31, 2025Total Liabilities
918.29BKRWFY2025 · Dec 31, 2025Total Non-current Assets
1.71TKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
592.05BKRWFY2025 · Dec 31, 2025Total Current Liabilities
326.24BKRWFY2025 · Dec 31, 2025Cash Equivalents
105.55BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
105.55BKRWFY2025 · Dec 31, 2025Other Short-term Investments
800.75BKRWFY2025 · Dec 31, 2025Accounts Receivable
122.01BKRWFY2025 · Dec 31, 2025Inventory
189.20BKRWFY2025 · Dec 31, 2025Accounts Payable
35.29BKRWFY2025 · Dec 31, 2025Short-term Debt
3.75BKRWFY2025 · Dec 31, 2025Other Current Liabilities
-70.00KRWFY2025 · Dec 31, 2025Long-term Debt
466.23BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-60.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
39.22BKRWFY2025 · Dec 31, 2025Retained Earnings
445.26BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
2.04TKRW1.47B · vs all stocks (USD)
52-Week Low
31.80KKRWUpdated Sep 21, 202652-Week High
61.30KKRWUpdated Sep 21, 202652-Week Change
-28.34%vs all stocks
Beta
0.8800xvs all stocks
50-Day MA
36.19KKRWUpdated Sep 21, 2026200-Day MA
42.77KKRWUpdated Sep 21, 2026Avg 10-Day Volume
66.69KSharesUpdated Sep 21, 2026Avg 30-Day Volume
77.97KSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-733.00KRWUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.55: grey zoneSignificant
Altman Z-Score: 2.55
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$203.18M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -203,178,335.29Global P5: -202,685,365.334
Market cap is $2.02B, above the global median of $1.18BNotable
Market cap (USD): 2,017,514,810.875Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Nuvation Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Mesoblast Limited
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Urogen Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inspire Medical Systems, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vazyme Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk